Protillion Biosciences appoints Robert Hollingsworth as chief scientific officer

Protillion Biosciences announced the hiring of Robert Hollingsworth as its new chief scientific officer. Hollingsworth joins Protillion after serving as chief scientific officer at Shoreline Therapeutics.

Before Shoreline, he spent time at Pfizer, where he was vice president and chief scientific officer for cancer vaccines and immunotherapeutics. His experience spans vaccine development and immunotherapy research.

The announcement appeared in a STAT+ column that regularly highlights personnel moves in the pharmaceutical industry. The piece invites readers to share their own hiring and promotion news.

The hiring reflects Protillion’s focus on advancing its pipeline with seasoned leadership in oncology and immunology.